• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
TechCloud Computing

Medical researchers use the cloud to do what they couldn’t before

Barb Darrow
By
Barb Darrow
Barb Darrow
Down Arrow Button Icon
Barb Darrow
By
Barb Darrow
Barb Darrow
Down Arrow Button Icon
June 19, 2015, 10:55 AM ET
<h1>DNA Rx</h1>


In 2003, a team of researchers working for the Department of Energy and the National Institutes of Health completed a 13-year long effort called the Human Genome Project. The goal of the project was, among other things, to identify and map every gene in human DNA. For a while, the scientific community has been looking at the data and wondering, "So, what's next?" 


One answer is targeted therapy, medical treatments that do not only address symptoms, but also respond to a patient's genetic makeup. 


The past couple of years have yielded breakthroughs in this field. In 2011, a team of scientists at the University of Pennsylvania effectively treated leukemia patients by engineering their own white blood cells to fight the disease. Also in 2011, researchers in Britain achieved promising results in treating the genetic disease hemophilia B by injecting patients with a re-engineered version of the gene. 2012 brought even more advancements, using targeted therapy to treat inherited blindness.


"Talk about transforming an industry," says George Day, co-director of the Mack Center at Wharton. "Big Pharma has always been pill-based," he says, meaning patients need daily dosage, whereas "gene therapy is one and done.


"I think finally after 20 years, the promise of gene therapy is starting to be realized."
<h1>DNA Rx</h1> In 2003, a team of researchers working for the Department of Energy and the National Institutes of Health completed a 13-year long effort called the Human Genome Project. The goal of the project was, among other things, to identify and map every gene in human DNA. For a while, the scientific community has been looking at the data and wondering, "So, what's next?" One answer is targeted therapy, medical treatments that do not only address symptoms, but also respond to a patient's genetic makeup. The past couple of years have yielded breakthroughs in this field. In 2011, a team of scientists at the University of Pennsylvania effectively treated leukemia patients by engineering their own white blood cells to fight the disease. Also in 2011, researchers in Britain achieved promising results in treating the genetic disease hemophilia B by injecting patients with a re-engineered version of the gene. 2012 brought even more advancements, using targeted therapy to treat inherited blindness. "Talk about transforming an industry," says George Day, co-director of the Mack Center at Wharton. "Big Pharma has always been pill-based," he says, meaning patients need daily dosage, whereas "gene therapy is one and done. "I think finally after 20 years, the promise of gene therapy is starting to be realized." Illustration: Alfred Pasieka/Getty Images

Cloud computing—and the ability it gives researchers to quickly add and shut down resources as needed—means that they can do massive number crunching that researchers could not have dreamed of in the past.

That’s probably one reason that Matthew Trunnell will upgrade legacy software at Seattle’s Fred Hutchinson Cancer Research Center to rely more on the cloud, according to the the Wall Street Journal. Trunnell, who is now CIO of the Broad Institute in Cambridge, Mass., will join Hutchinson as CIO in a few months.

Trunnell cited cloud computing as a way to advance “precision medicine” which is the practice of sequencing the genome of tumors and applying big data analytics to improve care.

The real key here is that the advent of huge web-scale computational capability—applying tens of thousands of computer nodes to a problem— brings supercomputer-like power to bear on very tough problems. In the past researchers who needed that sort of heavy-lifting had to sign up for time at one of the nation’s supercomputing centers. And then they waited, for weeks if not months. That’s clearly not optimal in for a specialty that wants to work fast and iteratively on tough problems.

Cycle Computing, which makes software that manages research applications so they can run across clouds, sees a lot of these applications moving to the cloud up close and personal.

“Every day, we witness engineers and scientists benefit from limitless access to compute, thanks to cloud,” said Cycle CEO Jason Stowe. “Steve Litster’s team at Novartis ran 40 years of cancer drug simulation in 8 hours, for thousands of dollars instead of millions. The critical value of cloud [computing] is not saving dollars, it is enabling researchers to do things they couldn’t do before.”

Litster is global lead for high-performance and scientific computing for the Novartis (NVSEF) Institutes for Biomedical Research

There are other examples of cloud computing being put to use in big projects, one being Autism Speaks’ use of Google(GOOG) Cloud for its genomic research.

Trunnell said the Broad Institute is testing Amazon(AMZN) and Google clouds now, and he plans to talk to those companies, as well as Microsoft(MSFT), when he starts his new job.

Subscribe to Data Sheet, Fortune’s daily newsletter on the business of technology.

About the Author
Barb Darrow
By Barb Darrow
See full bioRight Arrow Button Icon

Latest in Tech

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Tech

CommentaryEuropean Union
Europe’s second chance on AI: building an opportunity in factories, labs, and the real economy
By François Candelon, Theodoros Evgeniou and Thomas RamgeMarch 13, 2026
44 minutes ago
ELON
AIData centers
Morgan Stanley warns an AI breakthrough Is coming in 2026 — and most of the world isn’t ready
By Nick LichtenbergMarch 13, 2026
3 hours ago
Microsoft Corp. signage at the Nasdaq MarketSite in New York, US, on Wednesday, Dec. 24, 2025. A relatively quiet session on Wall Street before Christmas saw stocks hitting all-time highs, with more signs the jobs market is not quickly deteriorating supporting bets on a soft economic landing. Photographer: Michael Nagle/Bloomberg via Getty Images
InvestingMicrosoft
Microsoft’s IPO turns 40 today. If you invested $1,000 in Microsoft in 1986, you’d have $5.5 million today
By Catherina GioinoMarch 13, 2026
3 hours ago
Vinod Khosla
SuccessCareers
Billionaire Vinod Khosla says ‘follow your passion’ is bad career advice for kids today—but could be the best in 15 years
By Preston ForeMarch 13, 2026
3 hours ago
MagazineHollywood
The Oscars’ Best Picture category exposes a harsh new reality for Hollywood
By Geoff ColvinMarch 13, 2026
3 hours ago
AI
AIProductivity
Morgan Stanley sees AI jobs surge in 3 areas related to AI—even though there’s not enough revenue yet
By Nick LichtenbergMarch 13, 2026
4 hours ago

Most Popular

placeholder alt text
Economy
'This cannot be sustainable': The U.S. borrowed $50 billion a week for the past five months, the CBO says
By Eleanor PringleMarch 10, 2026
3 days ago
placeholder alt text
AI
'Proceed with caution': Elon Musk offers warning after Amazon reportedly had mandatory meeting to address 'high blast radius' and AI-related incidents
By Sasha RogelbergMarch 11, 2026
2 days ago
placeholder alt text
Future of Work
'I don't know if we're ready': Governors from each party appalled at 100-year-old federal workforce strategy
By Catherina GioinoMarch 12, 2026
20 hours ago
placeholder alt text
North America
The U.S. Mint dropped the olive branch from the dime. What does that mean for the country?
By Catherina GioinoMarch 12, 2026
11 hours ago
placeholder alt text
Success
BlackRock is splashing $100 million on training plumbers, electricians, and HVAC technicians as its CEO flags a skilled trade worker shortage
By Preston ForeMarch 11, 2026
2 days ago
placeholder alt text
AI
Sam Altman admits AI is killing the labor-capital balance—and says nobody knows what to do about it
By Nick LichtenbergMarch 12, 2026
20 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.